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Abstract
Purpose Altered methylation at Insulin-like Growth
Factor 2 (IGF2) regulatory regions has previously been
associated with obesity, and several malignancies including
colon, esophageal, and prostate adenocarcinomas, pre-
sumably via changes in expression and/or loss of imprint-
ing, but the functional signiﬁcance of these DNA
methylation marks have not been demonstrated in humans.
We examined associations among DNA methylation at
IGF2 differentially methylated regions (DMRs), circulat-
ing IGF2 protein concentrations in umbilical cord blood
(UCB) and birth weight in newborns.
Methods Questionnaire data were obtained from 300
pregnant women recruited between 2005 and 2009. UCB
DNA methylation was measured by bisulﬁte pyrose-
quencing. UCB plasma concentrations of soluble IGF2
were measured by ELISA assays. Generalized linear
regression models were used to examine the relationship
between DMR methylation and IGF2 levels.
Results Lower IGF2 DMR methylation was associated
with elevated plasma IGF2 protein concentrations (b =
-9.87, p\0.01); an association that was stronger in infants
born to obese women (pre-pregnancy BMI[30 kg/m
2,
b =- 20.21, p\0.0001). Elevated IGF2 concentrations
were associated with higher birth weight (p\0.0001) after
adjusting for maternal race/ethnicity, pre-pregnancy BMI,
cigarettesmoking,gestationaldiabetes,andinfantsex.These
patterns of association were not apparent at the H19 DMR.
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DOI 10.1007/s10552-012-9932-yConclusion Our data suggest that variation in IGF2 DMR
methylation is an important mechanism by which circu-
lating IGF2 concentrations, a putative risk factor for
obesity and cancers of the colon, esophagus, and prostate,
are modulated; associations that may depend on pre-preg-
nancy obesity.
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Introduction
The ‘developmental origins of adult disease susceptibility’
hypothesis posits that environmental exposures early in the
development permanently alter the phenotype, inﬂuencing
susceptibility to lifetime risk of obesity and several cancers
[1]. These alterations are thought to be mechanistically
driven by epigenetic alterations. The most stable and well-
studied epigenetic mechanism is DNA methylation, which
involves the covalent attachment of a methyl group to the
5-carbon position of the pyrimidine ring of cytosine resi-
dues when in 50-CpG-30 context. This epigenetic modiﬁ-
cation is faithfully transmitted to nascent DNA molecules
during DNA replication and is maintained during somatic
cell proliferation. DNA methylation contributes to the
induction and maintenance of transcriptional gene silenc-
ing, propagating shifts in gene expression that orchestrate
long-term susceptibility to several adenocarcinoma
including colon [2, 3], ovary [4], prostate [5, 6], stomach
[7], and esophagus [8]. Epigenetic mechanisms have also
been hypothesized to link birth weight, a proxy for the well-
being of the offspring in utero,with some of these cancers in
adulthood [9–15]. However, genomic regions in which
DNA methylation increases risk of these chronic diseases
are still unknown. Ultimately, cancer prevention will
require identiﬁcation of aberrant epigenetic proﬁles driving
risk, demonstration of their functional signiﬁcance as well
as environmental exposures associated with their pertur-
bation and ‘windows’ of susceptibility during life’s course.
Identiﬁcation of aberrant DNA methylation marks has
been hampered by a lack of stable targets with known
baseline levels, allowing for deviations from baseline to be
detected. The need for epidemiologic studies to use spec-
imens obtained from non-invasive means, such as periph-
eral blood leukocytes or buccal cells, which are often the
only tissues available in population-based studies, has
presented additional hurdles; epigenetic regulation and
dysregulation can vary by tissue and cell type. Genomically
imprinted genes are among several major classes of genes
that are regulated by DNA methylation [16]. Unlike most
autosomal genes that follow Mendelian laws of inheri-
tance where both parentally derived alleles are expressed,
imprinted genes are monoallelically expressed, with their
functional haploidy controlled by parental allele-speciﬁc
DNA methylation at differentially methylated regions
(DMRs). Because these methylation marks are stable
covalent modiﬁcations that are established before germ
layer speciﬁcation [17], these methylation proﬁles should
be maintained in all germ layers, resulting in quantiﬁable
systemic homogeneity in locus-speciﬁc epigenetic regula-
tion [17, 18]. As such, imprinted DMRs stably exhibit
*50% methylation in somatic tissues.
Insulin-like-growth factor-2 (IGF2) is perhaps the most
intensively studied imprinted gene and is paternally
expressed, with at least two regulatory DMRs located
upstream of exon 3 and upstream of neighboring mater-
nally expressed H19 [19]. Hypermethylation (methylation
fractions higher than the expected *50%) at the H19 DMR
[2, 4] and CpG hypomethylation (methylation fractions
lower than the expected *50%) at the IGF2 DMR [2] have
been associated with higher IGF2 mRNA levels suggesting
increased transcriptional activity, presumably via relaxa-
tion of imprint controls. Such increased transcriptional
activity is a common feature in adenocarcinomas of the
ovary, esophagus and prostate [4, 8, 20–25]. IGF2 DMR
loss of methylation was observed in DNA that was
obtained from peripheral blood leukocytes of adults
exposed to severe caloric restriction periconeptionally,
suggesting methylation shifts in response to adverse events
occur early and are stable over many decades [26]. Based
on these observations, methylation status at regulatory
sequences of imprinted genes has been proposed as
‘archives’ or ‘biosensors’ of early exposure [27, 28].
However, the functional signiﬁcance of these DMR meth-
ylation marks has not previously been demonstrated in
epidemiologic studies. The objective of these analyses was
to examine variation in DMR methylation at sequences
regulating IGF2/H19, in relation to UCB plasma IGF2
protein concentrations. We also determined whether IGF2
protein concentrations are associated with variation in birth
weight, an indicator of maternal and fetal well-being.
Methods
Study participants
A detailed description of study participants has been pre-
viously reported [29]. Brieﬂy, between April 2005 and June
2009, 1101 eligible pregnant women seen at one of two
Durham, North Carolina, obstetric facilities were identiﬁed
through appointment logs and were invited to enroll in the
Newborn Epigenetics STudy (NEST), a multiethnic cohort
study. Approximately 85% (n = 940) provided written
consent to participate. Eligibility criteria were as follows:
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123age C18 years, English speaking, and an intent to use one
of two Durham County obstetric facilities which enabled
specimen collection at delivery. We excluded women
infected with HIV and those planning to have their new-
borns adopted. Women were identiﬁed through appoint-
ment logs of two prenatal clinics serving the above two
obstetrics care facilities: Duke maternal fetal medicine
(MFM) and Durham Regional Hospital Obstetrics, Durham
County, NC, as part of the NEST. Gestational ages at
enrollment were 19–42 weeks (median = 28 weeks). This
report is limited to 300 (32%) deliveries in whom DNA
methylation analyses were performed and protein mea-
surements are available. The 300 women are comparable to
the 940 women with respect to maternal age (mean age
29 years), obesity (body mass index [BMI], 28 kg/m
2), and
sex of offspring (49% men). This study was approved by
the Institutional Review Board at Duke University Medical
Center.
Data collection
Questionnaire data collection
A standardized questionnaire was either self-administered
or completed with a trained interviewer. The questionnaire
items included socio-demographic information including
marital status, educational attainment, race/ethnicity,
smoking history, and current smoking status, a history of
common chronic diseases and conditions, dietary supple-
ment use, weight and height before pregnancy (from which
BMI and weight gain was computed). BMI was calculated
as pre-pregnancy weight in kilograms divided by height in
square meters (kg/m
2), and weight gain was the difference
between usual weight and weight at the delivery visit. At
delivery, medical records were abstracted to verify ciga-
rette smoking during pregnancy, reported morbidity and
age, and to obtain additional parturition data including
blood pressure and mode of delivery, body temperature and
chorioamnionitis (the latter two as indicators of infection
which may inﬂuence protein measurements), as well as
offspring information including sex, anthropometric mea-
surements, and 5-min Apgar scores.
Specimen collection and processing
Umbilical cord blood specimens were collected in vacu-
tainer tubes containing EDTA within minutes of delivery
and inverted gently to mix the anticoagulant with the
blood. Specimens were stored in the hospital refrigerator
until transported to the laboratory usually within 12 h of
collection where they were centrifuged to isolate plasma
and buffy coat, which was aliquotted and stored at -80C.
DNA was extracted from the white blood cells in the buffy
coat using Puregene reagents according to the manufac-
turer’s protocol (Qiagen, Valencia, CA).
Methylation measurements
Description of methylation measurements and primers used
has been described elsewhere [30]. Brieﬂy, cord blood
samples from the ﬁrst 438 subjects were analyzed for
methylation status at two DMRs controlling the expression
of IGF2. The steps comprised modiﬁcation of genomic
DNA by treating it with sodium bisulﬁte using a high-
throughput method previously described [4, 31] to convert
unmethylated cytosines to uracils, leaving methylated cy-
tosines unchanged. We then obtained a quantitative mea-
sure of methylation at each DMR using a Pyromark Q96
MD Pyrosequencing instrument (Qiagen; Valencia, CA).
Three CpGs were measured at the IGF2 DMR [2], located
upstream of the imprinted IGF2 promoter in exon 3, [2, 26]
(chr 11p15.5; CpG site 1: 2,169,518; CpG site 2:
2,169,515; and CpG site 3: 2,169,499; NCBI Human
Genome Build 37/hg19). We also measured DNA meth-
ylation at four CpG dinucleotides at the H19 DMR at a
sequence motif that binds the CTCF zinc-ﬁnger protein
(chr 11p15.5; CpG site 1: 2,024,261, CpG site 2:
2,024,259, CpG site 3: 2,024,257, and CpG site 4:
2,024,254; NCBI Human Genome Build 37/hg19). Meth-
ylation data were 98% complete. We validated both py-
rosequencing assays using deﬁned mixtures of plasmids
containing the fully methylated or unmethylated versions
of the bisulfate-modiﬁed sequence.
Protein measurements
Plasma concentrations of IGF2 were measured using
microplate enzyme-linked immunosorbent assays (Diag-
nostic Systems Laboratories, Webster, TX). Procedures for
measurement followed the manufacture’s instructions.
Absorbance was read using a microplate reader DSL,
Webster, TX. The plasma IGF2 concentrations ranged from
50 to 2,000 ng/ml, and assay sensitivity was 2.2 ng/ml.
Statistical analyses
For analyses, maternal age at enrollment was categorized
as 18–30, 30–39 versus 40 years or older; marital status
was dichotomized into married/living with partner versus
not married; educational level was categorized into groups
deﬁned as up to high school, some college to college
graduate versus graduate/professional school; race/ethnic-
ity was categorized into African Americans versus non-
Hispanic White versus other, cigarette smoking was
dichotomized into smoking during pregnancy versus not
smoking; birth weight was treated as both a continuous
Cancer Causes Control (2012) 23:635–645 637
123variable and dichotomized at less\2500 versus C2500 g;
maternal BMI was categorized into \25, 25–29, 30–34,
and 35 ? kg/m
2; weight gain during pregnancy was
dichotomized at\30 pounds versus C30 pounds; delivery
mode was classiﬁed as vaginal vs. C-section; and histo-
logical evidence of chorioamnionitis was dichotomized as
yes or no.
We examined the distribution of methylation fractions
for normality at each CpG dinucleotide using Kolmogorov–
Smirnov tests followed by principal components and con-
ﬁrmatory factor analyses to determine whether methylation
at the three CpGs measured in the IGF2 DMR and the four
CpGs measured at the H19 DMR were correlated to justify
the use of a single mean for each DMR. Cronbach’s alpha
values for CpGs were 86 and 87% at the IGF2 DMR and
H19 DMR, respectively. We also examined the distribu-
tions of birth weight, IGF2 proteins, maternal weight gain
and usual BMI for normality and found that with the
exception of maternal BMI and weight gain, these vari-
ables were normally distributed among the 300 partici-
pants under study. Thus, subsequent analyses dichotomized
maternal BMI at B30 kg/m
2, and weight gain at the 75th
percentile.
The main goal of our analyses was to determine whether
DNA methylation fractions at each DMR were associated
with IGF2 protein concentrations. Although race/ethnicity
and adult BMI have been previously associated with IGF2
concentrations and will be considered potential confound-
ers, F-tests were used to identify additional potential con-
founders, by identifying factors associated with statistically
signiﬁcant variation (p B 0.20) in IGF2 protein concen-
trations, and methylation levels at each DMR. In addition,
chorioamnionitis was examined for potential effect modi-
ﬁcation and confounding as previous studies of predictors
of IGF2 protein in otherwise healthy adults suggest acute
infection may affect protein concentrations [32]. Mode of
delivery was evaluated for potential confounding or effect
modiﬁers also because animal data suggests DNA meth-
ylation patterns may vary by delivery mode [33]. Because
75% of African Americans in this study were [30 kg/m
2
compared to 25% of Whites, we ﬁtted linear regression
models to examine the relationship between IGF2 protein
and DMR methylation for African Americans and Whites
and also for obese and non-obese women, separately. To
further examine the association IGF2 DMR methylation
and the protein product in the context of pre-pregnancy
BMI or weight gain during the course of pregnancy, we
repeated our analyses restricted to infants born to women
[30 versus B30 kg/m
2 and also gain weight below and
above the 75th percentile. Cross-product terms for maternal
BMI and DNA methylation at each DMR were also com-
puted and included in statistical models where differences
were observed in stratiﬁed analyses. Only variables with
p value\0.05 were retained in ﬁnal statistical models. To
examine whether IGF2 protein concentrations were asso-
ciated with birth weight, we also utilized linear regression
models since birth weight was normally distributed. These
latter models were adjusted for gestational diabetes,
maternal BMI, race/ethnicity, and cigarette smoking, as
these factors are known to independently inﬂuence birth
weight in the general population. All statistical analyses
were conducted in SAS version 9.3 (SAS Institute, Cary,
NC, USA).
Results
IGF2 proteins and covariable
The average UCB plasma protein concentration of IGF2
among the newborns was 1029 ng/ll, standard deviation
(SD = 458) (Table 1). Mean IGF2 concentration did not
vary signiﬁcantly by maternal age (p = 0.51), marital
status (p = 0.82), smoking during pregnancy (p = 0.83),
chorioamnionitis (p = 0.87) or indicators of maternal
socioeconomic status such as educational attainment (p =
0.32) and type of health insurance coverage (p = 0.22)
although ﬁve individuals with no insurance had signiﬁ-
cantly lower IGF2 levels. We observed lower IGF2 con-
centration in infants who were male (p value = 0.11), had
low birth weight (p value = 0.12), those born by C-section
(p value = 0.006) or to African American women
(p value = 0.02). IGF2 concentrations were also lower in
infants born to women with a pre-pregnancy BMI[30
(p value = 0.06) and those for whom pregnancy weight
gain was\30 lbs (p value = 0.09).
IGF2 and H19 DMR methylation and covariables
Table 2 shows the distribution of DNA methylation levels
by maternal and infant characteristics that were associated
with variation in IGF2 protein concentrations in Table 1.
Overall, average methylation levels among the newborns
were 48.5% (SD = 7.7) and 61.4% (SD = 7.7) at the IGF2
and H19 DMRs, respectively. At the IGF2 DMR, meth-
ylation percentages were similar by race/ethnicity, sex,
birth weight, delivery mode, weight gain during pregnancy,
and BMI before pregnancy (p values[0.20) (Table 2).
However, we observed slight methylation differences in
infants born to women with and those without histological
evidence of chorioamnionitis at delivery (p value \0.18);
chorioamnionitis was considered for confounding in the
IGF2 and H19 DMR analyses as it exhibited signiﬁcant
methylation differences at p B 0.20, as were race/ethnicity,
birth weight and three correlated factors; maternal BMI,
weight gain during pregnancy and mode of delivery.
638 Cancer Causes Control (2012) 23:635–645
123Table 1 Distribution of offspring IGF2 concentrations by maternal and offspring characteristics
IGF2 protein (ng/ll)
n % Mean SD p value
All participants 300 100 1028.78 457.75 –
Maternal age (in years)
\30 166 56.1 1000.69 450.61 0.509
30–39 112 37.8 1043.15 452.31
40? 18 6.1 1115.62 532.47
Missing 4 1.3
Marital status
Married/partner 173 59.0 1027.44 451.68 0.815
Never Married/divorced/widowed/separated 120 41.0 1014.69 466.31
Missing 7 2.3
Race
Black 156 54.2 963.52 435.62
Caucasian 114 39.6 1131.22 465.39 0.020
Asian 5 1.7 1041.97 372.83
Native American 2 0.7 1264.52 176.67
Other 11 3.8 828.52 536.52
Missing 12 4.0
Education
\HS/HSG/GED 117 39.0 991.76 477.33
Some college/college graduate 175 58.3 1046.07 441.82 0.320
Missing 8 2.7
Insurance
Public 176 58.7 991.92 461.93 0.111
Private 114 38.0 1082.43 447.83
No insurance 5 1.7 760.89 292.81
Missing 5 1.7 – –
Smoking
Non-smoker during peri-conception 244 81.3 1026.01 456.39 0.827
Smoker during peri-conception 56 18.7 1040.84 467.57
Birth weight
B2,500(B5 lb 8.2 oz) 43 14.3 922.61 476.02 0.121
[2,500 ([5 lb 8.2 oz) 249 83.0 1039.44 450.69
Missing 8 2.7
Sex of offspring
Male 151 50.3 974.90 427.26 0.109
Female 143 47.7 1076.17 481.48
Missing 6 2.0 – –
Maternal BMI (kg/m
2)
\25 133 44.3 1071.60 486.77
25–29 57 19.0 974.44 409.15
30–34 37 12.3 956.84 445.88 0.175
35? 39 13.0 919.73 346.13
Missing 34 11.3 – –
Weight gain during pregnancy
\30 lbs 197 65.7 989.65 429.97 0.088
[30 lbs 96 32.0 1086.81 504.30
Missing 7 2.3 – –
Cancer Causes Control (2012) 23:635–645 639
123H19 DMR methylation and IGF2 protein
concentrations
Overall, we found a signiﬁcant association between H19
DMR methylation (b =- 8.08, p = 0.02) and IGF2 pro-
tein concentrations (Table 3). However, adjusting for
maternal BMI before pregnancy weakened this association
(b =- 4.69, p = 0.07) (data not shown), and additionally
adjusting for chorioamnionitis and race/ethnicity further
weakened this association (b =- 3.64, p = 0.33). This
association may be stronger in infants born to African
Americans (b =- 6.90, p = 0.15) than those to Whites
(b =- 2.54, p = 0.68), although neither reached statistical
signiﬁcance. However, BMI-speciﬁc analyses suggested
this association may be more pronounced in infants born to
non-obese women (b =- 8.52, p = 0.09) compared to
those born to obese women (b = 0.33, p = 0.95). Further
adjustment for BMI, weight gain, and mode of delivery did
Table 2 IGF2 and H19 DMR
methylation fractions and
maternal and offspring
characteristics
IGF2 DMR % (sd) H19 DMR % (sd) p value
All participants 48.5 (7.7) 61.4 (7.7) –
Race/ethnicity
African American 48.4 (9.5) 62.1 (8.3)
White 48.2 (5.3) 60.7 (7.1)
Other 50.0 (5.6) p = 0.742 59.4 (7.0) p = 0.199
Sex of offspring
Male 48.4 (6.7) 61.7 (8.4)
Female 48.3 (8.8) p = 0.289 60.9 (7.1) p = 0.478
Birth weight
B2,500(B5 lb 8.2 oz) 48.6 (9.4) 59.8 (6.5)
[2,500 ([5 lb 8.2 oz) 48.3 (7.5) p = 0.875 61.5 (8.0) p = 0.194
Maternal BMI (kg/m
2)
\25 48.8 (5.8) 60.7 (6.6)
25–29 49.7 (10.2) 61.2 (7.4)
30–34 49.3 (8.5) 63.0 (9.6)
35? 47.5 (6.2) p = 0.618 62.0 (9.1) p = 0.390
Weight gain during pregnancy
\30 lbs 48.7 (8.7) 61.9 (8.5)
[30 lbs 47.9 (4.8) p = 0.487 60.1 (6.0) p = 0.079
Chorioamnionitis
Yes 46.0 (7.0) 58.8 (5.9)
No 48.7 (7.7) p = 0.180 61.6 (7.8) p = 0.128
Delivery route
Vaginal 48.7 (8.9) 61.4 (7.7)
C-section 48.2 (6.0) p = 0.634 61.3 (7.9) p = 0.950
Table 1 continued
IGF2 protein (ng/ll)
n % Mean SD p value
Delivery Route
Vaginal 170 56.7 1086.13 451.76 0.006
C-section 126 42.0 939.58 449.59
Missing 4 1.3 – –
Chorioamnionitis
Yes 22 7.3 1044.34 397.05 0.869
No 278 92.7 1027.55 462.82
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123not alter these ﬁndings. Analyses restricted to weight gain
cutoff at the 75th percentile revealed no additional insights
as the patterns of association between H19 DMR methyl-
ation and IGF2 protein levels were similar to those of the
analyses stratiﬁed by pre-pregnancy BMI (data not shown).
IGF2 DMR methylation and IGF2 protein
concentrations
Table 3 also shows that hypomethylation at the IGF2 DMR
was signiﬁcantly associated with higher IGF2 protein con-
centrations (b =- 9.87, p = 0.01). Adjusting for maternal
BMI pre-pregnancy strengthened this association (b =
-11.36, p = 0.01) and further adjusting for chorioamnio-
nitis, birth weight and race/ethnicity did not alter this
association. This association may be stronger in African
Americans (p = 0.06) than Whites (p = 0.31). Analyses
stratiﬁed by maternal BMI before pregnancy revealed an
association between IGF2 DMR methylation and IGF2
protein levels, which was considerably stronger in infants
born to obese women (b =- 20.41, p = 0.003) corre-
sponding to *110 ng/ll increase in IGF2 protein concen-
tration for every 5% decrease in DNA methylation levels at
the IGF2 DMR. The magnitude of this association was
markedly weaker in infants born to non-obese women
(b =- 4.75, p = 0.37). The cross-product term for obesity
and IGF2 DMR methylation, however, was not statistically
signiﬁcant (p = 0.78). Because weight gain during preg-
nancy is strongly associated with pre-pregnancy BMI,
repeating these analyses within each stratum of pre-preg-
nancy weight gain also did not reveal any insight to clarify
the relative importance of these factors as the associations
were much stronger in the 71 infants born to women with
the largest weight gain ([75th percentile), when compared
to those who gained B75th percentile. Intriguingly, includ-
ingmaternal weight gain in models with pre-pregnancy BMI
and its cross-product term did not suggest weight gain was
an important factor in the association between IGF2 DMR
methylation and IGF2 protein concentration.
IGF2 protein concentrations and birth weight
The mean birth weight in this population (n = 300) was
3.14 kg, with more than 95% of infants in the 2.2–5.2 kg
range. We examined the association between IGF2 protein
levels in UCB plasma and birth weight and found a linear
increase in birth weight with increasing IGF2 protein levels
(b = 0.28, SE = 0.07, p = 0.0003) (Table 4). This asso-
ciation was free from the inﬂuence of factors known to be
associated with birth weight including maternal race/eth-
nicity, pre-pregnancy BMI, education, gestational diabetes,
cigarette smoking, and sex of infant. Table 4 also shows
that while maternal cigarette smoking was indepen-
dently but inversely associated with birth weight (b =
-230.2, p value = 0.009), pre-pregnancy BMI (b = 197.4,
p value = 0.01) and Caucasian race/ethnicity (167.6,
p value \0.0001) were positively associated with birth
weight. Further inclusion of weight gain only widened
conﬁdence intervals, but did not alter risk estimates.
Discussion
We examined DNA methylation within two regulatory
regions of imprinted IGF2 in relation to circulating IGF2
concentrations in UCB of newborns. We observed a
Table 3 Associations between
methylation fractions at IGF2
and H19 DMRs and IGF2
circulating concentrations
stratiﬁed by race and maternal
obesity
a Models determining whether
methylation at the H19 or IGF2
DMRs predict protein levels.
Models are adjusted in all
participants, for birth weight,
histological evidence of
chorioamnionitis at delivery,
maternal BMI before pregnancy
and race. Models stratiﬁed by
race/ethnicity and BMI were
adjusted for birth weight,
chorioamnionitis, and race/
ethnicity or maternal BMI
before pregnancy
IGF2 CpG methylation H19 CpG methylation
b SE p value b SE p value
All participants (n = 300)
Crude -9.87 3.90 0.01 -8.08 3.51 0.02
Adjusted
a -9.49 4.23 0.03 -3.64 3.72 0.33
African Americans (n = 156)
Crude -7.94 4.23 0.06 -10.37 4.35 0.02
Adjusted -8.89 4.70 0.06 -6.90 4.73 0.15
Whites (n = 114)
Crude -12.28 9.36 0.19 0.19 6.35 0.98
Adjusted -9.12 8.85 0.31 2.54 6.20 0.68
BMI\30 kg/m
2 (n = 190)
Crude -7.60 5.32 0.16 -8.52 5.03 0.09
Adjusted -4.75 5.32 0.37 -7.67 5.08 0.13
BMI C 30 kg/m
2 (n = 76)
Crude -20.21 5.94 0.00 0.33 5.14 0.95
Adjusted -20.41 6.51 0.00 1.36 5.38 0.80
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123signiﬁcant increase in IGF2 protein concentrations with
decrease in methylation levels at the IGF2 DMR. This
association was strongest among infants born to women
with a pre-pregnancy BMI[30, similar in African
Americans and Caucasians. Effect sizes of a similar mag-
nitude have been previously reported at the IGF2 DMR and
other regions [26, 34, 35]. We also evaluated IGF2 protein
concentrations in relation to birth weight, and observed
elevated IGF2 protein concentrations were associated with
a higher birth weight. We found no evidence for associa-
tions between CpG methylation at the H19 DMR and IGF2
protein concentration after adjusting for maternal obesity
and race/ethnicity. We provide the ﬁrst evidence for an
association between DNA methylation at the IGF2 DMR
and IGF2 protein concentrations. These ﬁndings are con-
sistent with the interpretation that DNA methylation at the
IGF2 DMR is functionally relevant to the production of the
potent mitogenic growth factor IGF2 and that soluble IGF2
independently contributes to variation in birth weight.
The exact mechanism by which loss of methyl groups at
the IGF2 DMR increases IGF2 protein concentrations,
exacerbated by maternal obesity, is still unknown, although
changes in DNA methylation on the maternally derived
allele has been shown to relax imprint controls, reactivat-
ing the otherwise silent maternally derived allele, which
has been shown in previous studies to increase IGF2
mRNA and presumably protein products. Because
imprinted genes are usually found in clusters [36] and their
regulation may be networked [37], methylation alterations
of this DMR have the potential for regulating (and dysre-
gulating) multiple genes on different chromosomes.
Therefore, methylation at this single DMR can provide
information on epigenetic dysregulation elsewhere in the
genome [18]. Using DNA obtained from leukocytes,
methylation differences of a similar magnitude were
reported among Gambians [17] and Dutch [26] adults who
were exposed to nutritional challenges periconceptionally.
Together, these ﬁndings support the idea that methylation
marks acquired in the periconceptional period is similar
across tissue types and is stable over many years. The
stability of DNA methylation marks at the IGF2 DMR
during a 3-year period was also recently reported among
adult population controls [38]. The small magnitude of
differences is also consistent with the contention that
methylation marks acquired as a result of adjustments to
perceived environment may not be as large as those found
in cancer [39, 40]). Strong inverse associations between
DNA methylation levels at the IGF2 DMR using DNA
obtained from leukocytes, biallelic expression of this
otherwise monoallelically expressed gene, and elevated
colon cancer risk [2, 38, 41] have been reported. In tissue
specimens, hypermethylation at the H19 DMR is also fre-
quent in cancers of the ovary [42], breast [43], esophagus
[44], and prostate [45]. The IGF2 and H19 DMRs have
been previously proposed as biomarkers, biosensors, or
archives of early exposures [2, 27, 28]. Therefore, our
ﬁndings of a strong relationship between lower methylation
at the IGF2 DMR and elevated IGF2 protein levels support
the use of DNA methylation levels at this and perhaps other
DMRs as biosensors or archives of early exposure. Dif-
ferences observed by maternal obesity may be partly
explained by genetic factors that also play a role in mod-
ulating IGF2 levels in the offspring.
Findings that protein levels of the mitogenic IGF2 are
strongly associated with decreased methylation at the IGF2
DMR and with birth weight support the interpretation that
variation in birth weight is modulated, at least in part, by
IGF2 plasticity. This may also be occurring at other DMRs,
if hypothesized co-regulation with other imprinted regions
[37] can be demonstrated. Previous studies have reported
an association between circulating IGF2 protein concen-
trations and high birth weight [46] as well as risk of obesity
[47] and several cancers [48, 49] in adulthood, suggesting
early exposures may contribute to the variation in birth
weight via epigenetic alterations.
Our inability to ﬁnd a consistent association between
H19 DMR methylation and IGF2 protein levels except
among the 188 infants born to women with BMI\30 was
Table 4 Regression model b-coefﬁcients and standard errors of the association between umbilical cord blood IGF2 protein concentrations and
birth weight (n = 278)
Characteristic/factor b SE p value
IGF2 protein concentrations (ng/ll) 0.275 0.075 0.0003
Race/ethnicity (African American vs. Caucasian) 167.6 39.57 \0.0001
Maternal cigarette smoking -230.17 88.57 0.0099
BMI before pregnancy (obese vs. non-obese) 197.43 80.23 0.0145
Gestational diabetes 137.35 125.28 0.2739
Sex of infant -50.52 67.77 0.4566
Sex, birth weight, or BMI could not be ascertained in 12 of 300 infants. Factors are mutually adjusted for each other. IGF2 protein levels are
associated with higher birth weight (p = 0.0003); association is independent of race/ethnicity, maternal cigarette smoking, pre-pregnancy BMI,
gestational diabetes, and sex
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123unexpected. Current thinking for transcriptional control of
the imprinted IGF2/H19 domain correlates increased DNA
methylation at the H19 DMR with failure to bind methyl-
ation sensitive CTCF, which can transcriptionally activate
IGF2 on the normally silent maternal chromosome [50–52].
We cannot exclude the possibility that these were chance
ﬁndings, since the statistical power to conduct multivariable
analyses may have been inadequate. However, others have
also failed to ﬁnd a relationship between methylation
at the H19 DMR and IGF2 transcription among children
conceived in vitro and in vivo [52] suggesting that at the
H19 DMR, other processes including genetic factors or
other unmeasured environmental stimuli may contribute to
increased IGF2 protein concentrations and body size,
independent of DNA methylation alterations.
The main limitation of this study is the small sample size
which, although more than adequate for examining crude
relationships among DMR methylation fractions, protein
IGF2 concentrations and birth weight, may have been inad-
equate for multivariable analyses, especially when testing
interaction by race and maternal BMI. Despite the need for
larger studies to clarify these relationships, the analyses
raised the possibility that maternal obesity, which may be
drivenbyotherfactorsincludinggeneticvariation,alsoplays
a role in modulating IGF2 concentrations. This suggests that
amoredetailedunderstandingoftheseepigenetictargetswill
require genetic analyses within the sequences under evalu-
ation. Another limitation is that DNA obtained from
unfractionatedbloodcontainingmultiplecelltypesmayhave
distinct epigenetic proﬁles depending on the cell population
analyzed. However, we have previously described the anal-
ysis of fractionated cord blood for methylation at the same
H19 and IGF2 DMRs, and the major cell types showed no
signiﬁcant differences in methylation levels [30]. Addition-
ally,overallwhitebloodcellcountsvaryandcouldconfound
the methylation fraction measures. However, inclusion of
chorioamnionitis during parturition into statistical models
did not alter our ﬁndings, suggesting variation in total cell
counts may not contribute to differences in methylation at
these DMRs. Furthermore, although we demonstrated an
association between DMR methylation and protein levels
downstream, we were limited by a lack of transcription data.
However, a positive correlation between the levels of IGF2
mRNA and DNA methylation at these DMRs has been pre-
viously reported. These limitations notwithstanding, our
ﬁndings suggest that IGF2 DMR plasticity is an important
mechanism by which IGF2 protein levels are modulated.
In summary, among 300 newborns, we found a strong
inverse association between DNA methylation at the IGF2
regulatory sequence and elevated plasma protein concen-
trations of the encoded mitogenic growth factor. This
relationship appeared to be stronger in infants born to
women who were obese before pregnancy, but not weight
gain. Higher IGF2 protein concentrations were also asso-
ciated with higher birth weight. Herein, we provide evi-
dence in support of the functional signiﬁcance of aberrant
methylation proﬁles at regulatory elements controlling the
expression of imprinted IGF2, supporting the use of IGF2
DMR methylation as an archive or biosensor of early
exposure. If co-regulation of imprinted domains can be
demonstrated in humans, and transcripts are also associated
with DNA methylation and protein levels for other
imprinted genes in the same population, our ﬁndings would
support the use of methylation marks in an imprint regu-
latory network to improve exposure assessment in studies of
cancer and other chronic diseases.
Acknowledgments We thank the parents and children of the
Newborn Epigenetics Study, research nurse Tammy Bishop, and
research personnel: Stacy Murray, Carole Grenier, Darby Kroyer,
Natasha Duggan, Suba Narasimhan, and James Nathan Yarnall for
enrolling and tracing participants, and processing the specimens; and
the obstetrics faculty and staff at Duke University and Durham
regional Hospitals, Durham, NC. This work was supported in part by
R21ES014947, R01ES016772, R01DK085173, K01CA104517 the
American Cancer Society (grant number ACS-IRG-83-006) and the
Fred and Alice Stanback Foundation. Dr. Susan Murphy was also
supported by the Duke Comprehensive Cancer Center and Duke
Environmental Health Sciences Research Center.
Conﬂict of interest The authors declare that they have no conﬂict
of interest.
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use, dis-
tribution, and reproduction in any medium, provided the original
author(s) and the source are credited.
References
1. Bateson P, Barker D, Clutton-Brock T et al (2004) Develop-
mental plasticity and human health. Nature 430:419–421
2. Cui H, Cruz-Correa M, Giardiello FM et al (2003) Loss of IGF2
imprinting: a potential marker of colorectal cancer risk. Science
299:1753–1755 New York, NY
3. Nowakowska-Zajdel E, Mazurek U, Ziolko E et al (2011)
Analysis of expression proﬁle of gene encoding proteins of signal
cascades activated by insulin-like growth factors in colorectal
cancer. Int J Immunopathol Pharmacol 24:781–787
4. Murphy SK, Huang Z, Wen Y et al (2006) Frequent IGF2/H19
domain epigenetic alterations and elevated IGF2 expression in
epithelial ovarian cancer. Mol Cancer Res 4:283–292
5. Jarrard DF, Bussemakers MJ, Bova GS, Isaacs WB (1995)
Regional loss of imprinting of the insulin-like growth factor II
gene occurs in human prostate tissues. Clin Cancer Res
1:1471–1478
6. Bhusari S, Yang B, Kueck J, Huang W, Jarrard DF (2011)
Insulin-like growth factor-2 (IGF2) loss of imprinting marks a
ﬁeld defect within human prostates containing cancer. Prostate
71:1621–1630
7. Zuo QS, Yan R, Feng DX et al (2011) Loss of imprinting and
abnormal expression of the insulin-like growth factor 2 gene in
gastric cancer. Mol Carcinog 50:390–396
Cancer Causes Control (2012) 23:635–645 643
1238. Xu W, Fan H, He X, Zhang J, Xie W (2006) LOI of IGF2 is
associated with esophageal cancer and linked to methylation
status of IGF2 DMR. J Exp Clin Cancer Res 25:543–547
9. Wu AH, McKean-Cowdin R, Tseng CC (2011) Birth weight and
other prenatal factors and risk of breast cancer in Asian-Ameri-
cans. Breast Cancer Res Treat 130:917–925
10. Forman MR, Cantwell MM, Ronckers C, Zhang Y (2005)
Through the looking glass at early-life exposures and breast
cancer risk. Cancer Invest 23:609–624
11. Bagchi S (2005) Intrauterine growth linked to aggressive prostate
cancer. Lancet Oncol 6:70
12. Eriksson M, Wedel H, Wallander MA et al (2007) The impact of
birth weight on prostate cancer incidence and mortality in a
population-based study of men born in 1913 and followed up
from 50 to 85 years of age. Prostate 67:1247–1254
13. Nilsen TI, Romundstad PR, Troisi R, Vatten LJ (2005) Birth size
and subsequent risk for prostate cancer: a prospective population-
based study in Norway. Int J Cancer 113:1002–1004
14. Akre O, Forssell L, Kaijser M et al (2006) Perinatal risk factors
for cancer of the esophagus and gastric cardia: a nested case-
control study. Cancer Epidemiol Biomarkers Prev 15:867–871
15. Kaijser M, Akre O, Cnattingius S, Ekbom A (2005) Preterm birth,
low birth weight, and risk for esophageal adenocarcinoma. Gas-
troenterology 128:607–609
16. Strathdee G, Sim A, Brown R (2004) Control of gene expression
by CpG island methylation in normal cells. Biochem Soc Trans
32:913–915
17. Waterland RA, Kellermayer R, Laritsky E et al (2010) Season of
conception in rural gambia affects DNA methylation at putative
human metastable epialleles. PLoS Genet 6:e1001252
18. Woodﬁne K, Huddleston JE, Murrell A (2011) Quantitative
analysis of DNA methylation at all human imprinted regions
reveals preservation of epigenetic stability in adult somatic tissue.
Epigenetics Chromatin 4:1
19. Murphy SK, Jirtle RL (2003) Imprinting evolution and the price
of silence. Bioassays 25:577–588
20. Murrell A, Ito Y, Verde G et al (2008) Distinct methylation
changes at the IGF2-H19 locus in congenital growth disorders
and cancer LOI of IGF2 is associated with esophageal cancer and
linked to methylation status of IGF2 DMR. PLoS ONE 3:e1849
21. Cui H, Niemitz EL, Ravenel JD et al (2001) Loss of imprinting of
insulin-like growth factor-II in Wilms’ tumor commonly involves
altered methylation but not mutations of CTCF or its binding site.
Cancer Res 61:4947–4950
22. Cui H, Onyango P, Brandenburg S, Wu Y, Hsieh CL, Feinberg
AP (2002) Loss of imprinting in colorectal cancer linked to hy-
pomethylation of H19 and IGF2. Cancer Res 62:6442–6446
23. Nakagawa H, Chadwick RB, Peltomaki P, Plass C, Nakamura Y,
de La Chapelle A (2001) Loss of imprinting of the insulin-like
growth factor II gene occurs by biallelic methylation in a core
region of H19-associated CTCF-binding sites in colorectal can-
cer. Proc Natl Acad Sci U S A 98:591–596
24. Sullivan MJ, Taniguchi T, Jhee A, Kerr N, Reeve AE (1999)
Relaxation of IGF2 imprinting in Wilms tumours associated with
speciﬁc changes in IGF2 methylation. Oncogene 18:7527–7534
25. Takai D, Gonzales FA, Tsai YC, Thayer MJ, Jones PA (2001)
Large scale mapping of methylcytosines in CTCF-binding sites in
the human H19 promoter and aberrant hypomethylation in human
bladder cancer. Hum Mol Genet 10:2619–2626
26. Heijmans BT, Tobi EW, Stein AD et al (2008) Persistent epi-
genetic differences associated with prenatal exposure to famine in
humans. Proc Natl Acad Sci U S A 105:17046–17049
27. Hoyo C, Murphy SK, Jirtle RL (2009) Imprint regulatory ele-
ments as epigenetic biosensors of exposure in epidemiological
studies. J Epidemiol Community Health 63:683–684
28. Heijmans BT, Tobi EW, Lumey LH, Slagboom PE (2009) The
epigenome: archive of the prenatal environment. Epigenetics
4:526–531
29. Hoyo C, Murtha AP, Schildkraut JM et al (2011) Folic acid
supplementation before and during pregnancy in the newborn
epigenetics study (NEST). BMC Public Health 11:46
30. Hoyo C, Murtha AP, Schildkraut JM et al (2011) Methylation
variation at IGF2 differentially methylated regions and maternal
folic acid use before and during pregnancy. Epigenetics 6:
928–936
31. Huang Z, Wen Y, Shandilya R, Marks JR, Berchuck A, Murphy
SK (2006) High throughput detection of M6P/IGF2R intronic
hypermethylation and LOH in ovarian cancer. Nucleic Acids Res
34:555–563
32. Umbers AJ, Boeuf P, Clapham C et al (2011) Placental malaria-
associated inﬂammation disturbs the insulin-like growth factor
axis of fetal growth regulation. J Infect Dis 203:561–569
33. Schlinzig T, Johansson S, Gunnar A, Ekstrom TJ, Norman M
(2009) Epigenetic modulation at birth—altered DNA-methylation
in white blood cells after caesarean section. Acta Paediatr 98:
1096–1099
34. Steegers-Theunissen RP, Obermann-Borst SA, Kremer D et al
(2009) Periconceptional maternal folic acid use of 400 microg per
day Is related to increased methylation of the IGF2 gene in the
very young child. PLoS ONE 4:e7845
35. Talens RP, Boomsma DI, Tobi EW et al (2010) Variation, pat-
terns, and temporal stability of DNA methylation: considerations
for epigenetic epidemiology. FASEB J 24:3135–3144
36. Edwards CA, Rens W, Clarke O et al (2007) The evolution of
imprinting: chromosomal mapping of orthologues of mammalian
imprinted domains in monotreme and marsupial mammals. BMC
Evol Biol 7:157
37. Varrault A, Gueydan C, Delalbre A et al (2006) Zac1 regulates an
imprinted gene network critically involved in the control of
embryonic growth. Dev Cell 11:711–722
38. Cruz-Correa M, Zhao R, Oviedo M et al. (2009) Temporal sta-
bility and age-related prevalence of loss of imprinting of the
insulin-like growth factor-2 gene. Epigenetics 4:114–118
39. Jirtle RL, Skinner MK (2007) Environmental epigenomics and
disease susceptibility. Nat Rev 8:253–262
40. Feinberg AP (2007) An epigenetic approach to cancer etiology.
Cancer J 13:70–74 (SudburyMass)
41. Cruz-Correa M, Cui H, Giardiello FM et al (2004) Loss of
imprinting of insulin growth factor II gene: a potential heritable
biomarker for colon neoplasia predisposition. Gastroenterology
126:964–970
42. Dammann RH, Kirsch S, Schagdarsurengin U et al (2010) Fre-
quent aberrant methylation of the imprinted IGF2/H19 locus and
LINE1 hypomethylation in ovarian carcinoma. Int J Oncol 36:
171–179
43. Yang R, Wang Y, Zhu X, Gao X (2009) Study on genomic
imprinting of IGF2 in breast cancer. Wei sheng yan jiu. J Hyg
Res 38:423–425
44. Zhao R, DeCoteau JF, Geyer CR, Gao M, Cui H, Casson AG
(2009) Loss of imprinting of the insulin-like growth factor II
(IGF2) gene in esophageal normal and adenocarcinoma tissues.
Carcinogenesis 30:2117–2122
45. Paradowska A, Fenic I, Konrad L et al (2009) Aberrant epigenetic
modiﬁcations in the CTCF binding domain of the IGF2/H19 gene
in prostate cancer compared with benign prostate hyperplasia. Int
J Oncol 35:87–96
46. Johnsen SP, Sorensen HT, Thomsen JL et al (2004) Markers of
fetal growth and serum levels of insulin-like growth factor (IGF)
I, -II and IGF binding protein 3 in adults. Eur J Epidemiol 19:
41–47
644 Cancer Causes Control (2012) 23:635–645
12347. Fowke JH, Matthews CE, Yu H et al (2010) Racial differences in
the association between body mass index and serum IGF1, IGF2,
and IGFBP3. Endocr Relat Cancer 17:51–60
48. Gronbaek H, Flyvbjerg A, Mellemkjaer L et al (2004) Serum
insulin-like growth factors, insulin-like growth factor binding
proteins, and breast cancer risk in postmenopausal women.
Cancer Epidemiol Biomarkers Prev 13:1759–1764
49. Shetty PJ, Movva S, Pasupuleti N et al (2011) Regulation of IGF2
transcript and protein expression by altered methylation in breast
cancer. J Cancer Res Clin Oncol 137:339–345
50. Murphy SK, Wylie AA, Coveler KJ et al (2003) Epigenetic
detection of human chromosome 14 uniparental disomy. Hum
Mutat 22:92–97
51. Murrell A, Ito Y, Verde G et al (2008) Distinct methylation
changes at the IGF2-H19 locus in congenital growth disorders
and cancer. PLoS ONE 3:e1849
52. Turan N, Katari S, Gerson LF et al (2010) Inter- and intra-indi-
vidual variation in allele-speciﬁc DNA methylation and gene
expression in children conceived using assisted reproductive
technology. PLoS Genet 6:e1001033
Cancer Causes Control (2012) 23:635–645 645
123